A nontandem novel compound chimeric antigen receptor redirected to target CD20-CD19 positive B-cell acute leukemias and B-cell lymphoma

Clin Transl Med. 2024 Jul;14(7):e1743. doi: 10.1002/ctm2.1743.

¹ Research & Development Division, iCell Gene Therapeutics Inc., Long Island High Technology Incubator, Stony Brook, New York, USA.
² Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
³ Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
⁴ Department of Advanced Diagnostic and Clinical Medicine, Zhongshan People's Hospital, Zhongshan, People's Republic of China.
⁵ Brown Center for Immunotherapy, Indiana University School of Medicine, Indianapolis, Indiana, USA.

No abstract available

Publication types